Loading resource…

Instituto Universitario CEMIC, Buenos Aires, Argentina; Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain; Vall d’Hebron University Hospital, Vall d’Hebron Institute of Research, Barcelona, Spain; Universidad
Tirzepatide has been recently approved for improving glycemic control in T2DM and shows promise in reducing cardiorenal risk factors. Clinical trials indicate that it may decrease albuminuria and slow the decline of estimated glomerular filtration rate (eGFR) in high-risk populations. The document discusses ongoing research and trials assessing its impact on cardiovascular events and kidney health, positioning tirzepatide as a potential therapeutic option for patients with T2DM and CKD.
No account needed